Movement Alert｜Duality Biotherapeutics-B Rises 5.33% in Regular Trading, Soochow Securities Initiates with Buy Rating and HK$418.61 Target Price

Market Focus07-08

On July 8, Duality Biotherapeutics-B rose 5.33% in regular trading, trading at HK$222.0/share, with turnover of approximately HK$74.52 million.

On the news front, Soochow Securities initiated coverage on the company with a Buy rating and a target price of HK$418.61, implying nearly 90% upside from the current share price. The initiation comes amid multiple positive catalysts, including the company's STAR Market IPO review status recently advancing to the inquiry stage, its previously announced share buyback plan of up to US$40 million, and the completion of first patient dosing in the global Phase III pivotal registration trial for DB-1311/BNT324, a B7-H3-targeting ADC co-developed with BioNTech for the treatment of metastatic castration-resistant prostate cancer.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1191425308?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-08 10:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1191425308","market":"us","top_or_hot":-1,"title":"Movement Alert｜Duality Biotherapeutics-B Rises 5.33% in Regular Trading, Soochow Securities Initiates with Buy Rating and HK$418.61 Target Price","media":"Market Focus","content":"<p><p>On July 8, Duality Biotherapeutics-B rose 5.33% in regular trading, trading at HK$222.0/share, with turnover of approximately HK$74.52 million.</p><p>On the news front, Soochow Securities initiated coverage on the company with a Buy rating and a target price of HK$418.61, implying nearly 90% upside from the current share price. The initiation comes amid multiple positive catalysts, including the company's STAR Market IPO review status recently advancing to the inquiry stage, its previously announced share buyback plan of up to US$40 million, and the completion of first patient dosing in the global Phase III pivotal registration trial for DB-1311/BNT324, a B7-H3-targeting ADC co-developed with BioNTech for the treatment of metastatic castration-resistant prostate cancer.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Duality Biotherapeutics-B Rises 5.33% in Regular Trading, Soochow Securities Initiates with Buy Rating and HK$418.61 Target Price</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Duality Biotherapeutics-B Rises 5.33% in Regular Trading, Soochow Securities Initiates with Buy Rating and HK$418.61 Target Price\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-08 10:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 8, Duality Biotherapeutics-B rose 5.33% in regular trading, trading at HK$222.0/share, with turnover of approximately HK$74.52 million.</p><p>On the news front, Soochow Securities initiated coverage on the company with a Buy rating and a target price of HK$418.61, implying nearly 90% upside from the current share price. The initiation comes amid multiple positive catalysts, including the company's STAR Market IPO review status recently advancing to the inquiry stage, its previously announced share buyback plan of up to US$40 million, and the completion of first patient dosing in the global Phase III pivotal registration trial for DB-1311/BNT324, a B7-H3-targeting ADC co-developed with BioNTech for the treatment of metastatic castration-resistant prostate cancer.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09606","symbol_name":"映恩生物-B","start_time":0,"source_url":"","article_id":"1191425308","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1191425308","pubTimestamp":1783476070,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 8, Duality Biotherapeutics-B rose 5.33% in regular trading, trading at HK$222.0/share, with turnover of approximately HK$74.52 million.On the news front, Soochow Securities initiated coverage...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09606":"映恩生物-B"},"translate_title":"异动快讯|Duality Biotherapeutics-B常规交易升5.33%东吴证券发起买入评级目标价418.61港元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09606":1},"content_text":"On July 8, Duality Biotherapeutics-B rose 5.33% in regular trading, trading at HK$222.0/share, with turnover of approximately HK$74.52 million.On the news front, Soochow Securities initiated coverage on the company with a Buy rating and a target price of HK$418.61, implying nearly 90% upside from the current share price. The initiation comes amid multiple positive catalysts, including the company's STAR Market IPO review status recently advancing to the inquiry stage, its previously announced share buyback plan of up to US$40 million, and the completion of first patient dosing in the global Phase III pivotal registration trial for DB-1311/BNT324, a B7-H3-targeting ADC co-developed with BioNTech for the treatment of metastatic castration-resistant prostate cancer.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1191425308","isCrawlerRequest":true}